Where to Get Biomarker Testing Done in Hyderabad

Biomarker testing is not performed at a single hospital counter — it is coordinated through accredited partner pathology and molecular-diagnostics laboratories, chosen for the specific test your case needs. A PD-L1 immunohistochemistry (IHC) stain and a broader MSI/TMB next-generation-sequencing (NGS) panel are often run at different specialised labs, sometimes in different parts of the city, because the two techniques use different equipment and expertise.

Your oncology team places the referral, tracks the sample through the lab, and receives the signed report — you don't have to independently identify or approach the lab yourself. This coordination model is deliberate: it lets each test go to whichever accredited facility is genuinely equipped to run it well, rather than routing everything through one in-house counter that may not carry every assay.

Biomarker testing for CION patients is coordinated at accredited partner laboratories, not run in-house. This page explains the pathway and terminology in general terms; it does not interpret your specific report or promise a particular treatment outcome.

Result bands shown are the commonly cited reference ranges used in NCCN/ASCO patient-education materials, indicative as of August 2026. Your oncologist interprets your specific report against your cancer type and the treatment being considered — this table is general education, not an eligibility statement.

1. 1

   Tissue is identified from an existing sample

   Most biomarker tests use the tissue block already collected during a prior biopsy or surgery — a fresh procedure is usually needed only if that sample is too old, too small, or poorly preserved.

2. 2

   Sample is sent to an accredited partner lab

   Your oncology team routes the request to the specific NABL/CAP-accredited lab equipped for that test — PD-L1 IHC and NGS panels are often processed at different specialised facilities.

3. 3

   Staining or sequencing is performed

   The lab stains the sample (for an IHC test like PD-L1) or sequences it (for MSI, TMB or a multi-gene panel), following the manufacturer-validated protocol for that assay.

4. 4

   A pathologist reviews and signs off the report

   Results are scored and reviewed by a qualified pathologist before the report is finalised — this is why turnaround takes days, not hours, even once the lab work itself is done.

5. 5

   Your oncology team discusses the report with you

   The signed report goes to your treating oncologist, who explains what it means for your options at a consultation — not as a number read out on its own.

*Indicative, as of August 2026. Actual cost and turnaround vary by lab, sample quality and the exact panel ordered — confirm both in writing before your sample is sent. Aarogyasri/scheme coverage for specific panels should be checked directly with the scheme and the lab.

• Lab accreditation — confirm the lab carries NABL accreditation, and CAP accreditation for specialised molecular panels.
• Right assay for the drug being considered — a PD-L1 clone validated for one drug isn't automatically valid for another; ask which clone or panel your case needs.
• Enough tissue on the block — very small or old samples can fail to give a usable result; ask upfront whether the existing sample is sufficient.
• Written cost and turnaround estimate — get this in writing before the sample is sent, since costs are indicative and vary by lab and panel.
• Who explains the result — confirm your oncology team, not the lab report alone, will walk you through what the result means for your options.

• Can Biomarker Testing Be Repeated on a Newer Sample? — what changes if your first sample is old or the result looks out of date.
• Why Two Labs Gave Different PD-L1 Results — why two accredited labs can report modestly different numbers on the same tissue.
• Biomarkers Beyond PD-L1: What Else Predicts Response — the other tests your oncologist may weigh alongside PD-L1.
• Immunotherapy at CION Cancer Clinics — the full picture of how CION supports patients through the immunotherapy decision and journey.

This page explains general biomarker-testing terminology and the sample pathway for education only, and does not interpret any individual patient's report or guarantee eligibility for any treatment. Testing is coordinated at accredited partner laboratories; bring your report to a consultation for a doctor's assessment of what it means for you.

Thousands of families have navigated this exact referral

A biomarker order can feel like one more confusing step. Our oncologists take the time to explain, in plain language, where testing happens, how long it takes, and what the result means for your options.